PT-141

Overview

PT-141, also known as Bremelanotide, is a synthetic peptide derived from Melanotan II through metabolic modification. Developed as a more targeted melanocortin receptor agonist, PT-141 represents an important research tool for studying the central nervous system mechanisms of sexual arousal and melanocortin receptor pharmacology.

Unlike its predecessor Melanotan II, PT-141 was specifically optimized for MC3R and MC4R receptor activation while having reduced affinity for MC1R. This selectivity shift makes it particularly valuable for research focused on the hypothalamic melanocortin pathways that regulate sexual function, independent of melanogenic effects.

PT-141 has been the subject of extensive clinical research and represents one of the first peptides studied for its central mechanism of action on sexual arousal, acting through neural pathways rather than peripheral vascular effects.

Chemical Profile

Mechanism of Action

PT-141 acts primarily through selective activation of melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting compounds, PT-141's mechanism is centrally mediated, targeting neural circuits that regulate sexual arousal and desire.

Upon binding to MC4R in the medial preoptic area and paraventricular nucleus of the hypothalamus, PT-141 activates downstream signaling cascades involving cAMP/PKA pathways. This triggers the release of oxytocin and dopamine, neurotransmitters directly involved in sexual arousal and motivation circuits.

The key distinction from Melanotan II is PT-141's reduced affinity for MC1R (melanocyte receptors), resulting in minimal melanogenic activity. Its selectivity for MC3R/MC4R makes it a cleaner research tool for studying the neural basis of sexual function without confounding pigmentation effects.

Research Applications

• MC3R/MC4R receptor activation and signaling
• Hypothalamic neural pathway modulation
• Sexual arousal mechanism research
• CNS-mediated sexual function studies
• Melanocortin receptor selectivity research
• Neuropeptide release cascade studies

Handling & Reconstitution

1. 1Allow the vial and sterile water to reach room temperature (15–25°C).
2. 2Using a sterile syringe, withdraw the appropriate volume of sterile water.
3. 3Inject the water slowly along the inside wall of the vial — do not spray directly onto the powder.
4. 4Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously.
5. 5Once reconstituted, store at 2°C – 8°C. Protect from light.
6. 6Use within 28 days after reconstitution.
7. 7Do not freeze reconstituted solution.